Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update
Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or...
Gespeichert in:
| Veröffentlicht in: | Progrès en urologie (Paris) 2009-04, Vol.19 Suppl 1, p.S15-S19 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S19 |
|---|---|
| container_issue | |
| container_start_page | S15 |
| container_title | Progrès en urologie (Paris) |
| container_volume | 19 Suppl 1 |
| creator | Drouin, S-J Rouprêt, M Davin, J-L Soulié, M |
| description | Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers. |
| doi_str_mv | 10.1016/S1166-7087(09)73901-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67284368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67284368</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-2ad3078ec71e3b0183fd81d16c129504f794a57b1fde085106aedba869d775373</originalsourceid><addsrcrecordid>eNo9kMlOxDAQRH0AMcPAJ4B8QnAIuOPECzc0YpMGcQDOwbE7IigbtoM0f48Ry6lb1a9KpSbkCNg5MBAXTwBCZJIpecr0meSaQSZ2yPJfXpD9EN4ZE4wpvUcWoAtRcp4vyesDutaajloTojexHQfaDjS-IY0eTexxiHRsaDcmqNtS4z7NYNHR0dMeYzIlj6WTH783TDHp6i-pGeg8uaQckN3GdAEPf-eKvNxcP6_vss3j7f36apNNwHXMcuM4kwqtBOQ1A8Ubp8CBsJDrkhWN1IUpZQ2NQ6ZKYMKgq40S2klZcslX5OQnN1X5mDHEqm-Dxa4zA45zqITMVcGFSuDxLzjXPbpq8m1v_Lb6-wn_AgSCYyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67284368</pqid></control><display><type>article</type><title>Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Drouin, S-J ; Rouprêt, M ; Davin, J-L ; Soulié, M</creator><creatorcontrib>Drouin, S-J ; Rouprêt, M ; Davin, J-L ; Soulié, M</creatorcontrib><description>Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers.</description><identifier>ISSN: 1166-7087</identifier><identifier>DOI: 10.1016/S1166-7087(09)73901-6</identifier><identifier>PMID: 19465332</identifier><language>fre</language><publisher>France</publisher><subject>Gonadotropin-Releasing Hormone - agonists ; Humans ; Male ; Neoplasm Staging ; Orchiectomy - methods ; Prostatectomy - methods ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Survival Analysis ; Time Factors</subject><ispartof>Progrès en urologie (Paris), 2009-04, Vol.19 Suppl 1, p.S15-S19</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19465332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drouin, S-J</creatorcontrib><creatorcontrib>Rouprêt, M</creatorcontrib><creatorcontrib>Davin, J-L</creatorcontrib><creatorcontrib>Soulié, M</creatorcontrib><title>Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update</title><title>Progrès en urologie (Paris)</title><addtitle>Prog Urol</addtitle><description>Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers.</description><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Orchiectomy - methods</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><issn>1166-7087</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMlOxDAQRH0AMcPAJ4B8QnAIuOPECzc0YpMGcQDOwbE7IigbtoM0f48Ry6lb1a9KpSbkCNg5MBAXTwBCZJIpecr0meSaQSZ2yPJfXpD9EN4ZE4wpvUcWoAtRcp4vyesDutaajloTojexHQfaDjS-IY0eTexxiHRsaDcmqNtS4z7NYNHR0dMeYzIlj6WTH783TDHp6i-pGeg8uaQckN3GdAEPf-eKvNxcP6_vss3j7f36apNNwHXMcuM4kwqtBOQ1A8Ubp8CBsJDrkhWN1IUpZQ2NQ6ZKYMKgq40S2klZcslX5OQnN1X5mDHEqm-Dxa4zA45zqITMVcGFSuDxLzjXPbpq8m1v_Lb6-wn_AgSCYyA</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Drouin, S-J</creator><creator>Rouprêt, M</creator><creator>Davin, J-L</creator><creator>Soulié, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update</title><author>Drouin, S-J ; Rouprêt, M ; Davin, J-L ; Soulié, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-2ad3078ec71e3b0183fd81d16c129504f794a57b1fde085106aedba869d775373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2009</creationdate><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Orchiectomy - methods</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drouin, S-J</creatorcontrib><creatorcontrib>Rouprêt, M</creatorcontrib><creatorcontrib>Davin, J-L</creatorcontrib><creatorcontrib>Soulié, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Progrès en urologie (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drouin, S-J</au><au>Rouprêt, M</au><au>Davin, J-L</au><au>Soulié, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update</atitle><jtitle>Progrès en urologie (Paris)</jtitle><addtitle>Prog Urol</addtitle><date>2009-04</date><risdate>2009</risdate><volume>19 Suppl 1</volume><spage>S15</spage><epage>S19</epage><pages>S15-S19</pages><issn>1166-7087</issn><abstract>Indications for hormonotherapy in prostate cancer are in deep mutation and are constantly evolving. Used initially (1941) in metastatic stages, hormone therapy is used nowadays in locally advanced prostate cancer and aggressive localized disease. Its prescription in association with radiotherapy or surgery has provided a benefit regarding survival free progression. The place of hormone therapy in localized prostate cancer is not well defined and the debate is still ongoing, especially in case of biochemical recurrence after irradiation or radical prostatectomy and even in neoadjuvant cases. Additional and further studies are ongoing and are strongly needed to establish new guidelines. Nevertheless, hormone therapy is not restricted any more to palliative cases and is part of the current therapeutic arsenal of the urologist for high risk localized and/or locally advanced prostate cancers.</abstract><cop>France</cop><pmid>19465332</pmid><doi>10.1016/S1166-7087(09)73901-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1166-7087 |
| ispartof | Progrès en urologie (Paris), 2009-04, Vol.19 Suppl 1, p.S15-S19 |
| issn | 1166-7087 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_67284368 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Gonadotropin-Releasing Hormone - agonists Humans Male Neoplasm Staging Orchiectomy - methods Prostatectomy - methods Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Survival Analysis Time Factors |
| title | Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A25%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20castration%20in%20the%20treatment%20of%20locally%20advanced%20or%20metastatic%20prostate%20cancer:%20an%20update&rft.jtitle=Progre%CC%80s%20en%20urologie%20(Paris)&rft.au=Drouin,%20S-J&rft.date=2009-04&rft.volume=19%20Suppl%201&rft.spage=S15&rft.epage=S19&rft.pages=S15-S19&rft.issn=1166-7087&rft_id=info:doi/10.1016/S1166-7087(09)73901-6&rft_dat=%3Cproquest_pubme%3E67284368%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67284368&rft_id=info:pmid/19465332&rfr_iscdi=true |